Latest Conference Articles

May 30th 2020, 5:30pm

ASCO Annual Meeting

Mirvetuximab soravtansine in combination with bevacizumab to treat patients with platinum-agnostic ovarian cancer demonstrated encouraging overall response rates regardless of platinum status with a favorable tolerability profile.

May 30th 2020, 4:54am

ASCO Annual Meeting

The allogeneic CAR-T cell therapy ALLO-501, paired with the monoclonal antibody ALLO-647, demonstrated clinical responses and manageable toxicity in patients with pretreated large B-cell and follicular lymphomas.

May 30th 2020, 3:16am

ASCO Annual Meeting

Idecabtagene vicleucel induced a response in nearly three-fourths of patients with heavily pretreated relapsed/refractory multiple myeloma, according to topline findings from the pivotal phase 2 KarMMA trial.

May 30th 2020, 2:40am

ASCO Annual Meeting

Scott Kopetz, MD, PhD, FACP, discusses the updated survival data from the BEACON CRC study in BRAF V600E–mutated metastatic colorectal cancer.

May 30th 2020, 2:19am

ASCO Annual Meeting

Nancy U. Lin, MD, discusses updated findings from the phase 2 HER2CLIMB study in patients with HER2-positive metastatic breast cancer with brain metastases.

May 30th 2020, 2:02am

ASCO Annual Meeting

Pembrolizumab in combination with several chemotherapy partners led to a statistically significant and clinically meaningful improvement in progression-free survival compared with chemotherapy alone as a first-line treatment for patients with locally recurrent, inoperable, or metastatic triple-negative breast cancer whose tumors expressed PD-L1.

May 30th 2020, 1:33am

ASCO Annual Meeting

Patients with previously treated HER2-positive metastatic breast cancer and brain metastases achieved significant intracranial responses with a combination of tucatinib plus trastuzumab and capecitabine, according to findings from a subset of patients in the HER2CLIMB trial.

May 30th 2020, 1:13am

ASCO Annual Meeting

Results from the CheckMate 9LA suggested that frontline treatment with nivolumab plus ipilimumab combined with 2 cycles of platinum-doublet chemotherapy in patients with metastatic or recurrent non-small cell lung cancer should be considered a new option for this population.

May 30th 2020, 12:40am

ASCO Annual Meeting

Joyce F. Liu, MD, MPH, discusses findings from a phase 2 study with the Wee1 inhibitor adavosertib in patients with recurrent uterine serous carcinoma.

May 29th 2020, 11:37pm

ASCO Annual Meeting

John Kuruvilla, MD, FRCPC, discusses findings from the phase 3 KEYNOTE-204 trial in Hodgkin lymphoma.

May 29th 2020, 11:32pm

ASCO Annual Meeting

Jesus Berdeja, MD, discusses updated results from the ongoing phase 1b/2 CARTITUDE-1 trial (NCT03548207) in multiple myeloma.

May 29th 2020, 11:18pm

ASCO Annual Meeting

Modest survival benefits were observed in patients with extensive-stage small cell lung cancer who received the combination of pembrolizumab and etoposide plus platinum compared with patients who received EP and placebo.

May 29th 2020, 11:06pm

ASCO Annual Meeting

When added to bortezomib and dexamethasone in patients with multiple myeloma, selinexor, an inhibitor of XPO1-mediated nuclear export, improves progression-free survival and overall response rate and reduces the incidence of peripheral neuropathy.

May 29th 2020, 11:01pm

ASCO Annual Meeting

A phase III study using cediranib and olaparib to treat recurrent platinum-sensitive ovarian cancer did not meet its primary endpoint of progression-free survival but did produce comparable activity to standard of care platinum-based chemotherapy treatment.

May 29th 2020, 10:45pm

ASCO Annual Meeting

Following at least 3 years of follow-up, patients with advanced non-small cell lung cancer and tumor PD-L1 expression ≥ 1% or < 1% experienced durable and long-term efficacy benefits from frontline treatment with nivolumab plus ipilimumab, compared with chemotherapy.

May 29th 2020, 10:36pm

ASCO Annual Meeting

Over half of patients with PIK3CA-positive, HR-positive/HER2-negative advanced breast cancer who had prior treatment with a CDK4/6 inhibitor plus an aromatase inhibitor were alive without disease progression 6 months after starting treatment with alpelisib plus fulvestrant.

May 29th 2020, 10:04pm

ASCO Annual Meeting

The chimeric antigen receptor T-cell therapy, JNJ-4528, continued to demonstrate deep and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma, according to updated findings from the phase 1b/2 CARTITUDE-1 (NCT03548207) trial.

May 29th 2020, 9:48pm

ASCO Annual Meeting

Belantamab mafodotin in combination with bortezomib (Velcade) and dexamethasone (B-Vd) demonstrated a high rate of clinical benefit and an acceptable safety profile in patients with relapsed or refractory multiple myeloma.

May 29th 2020, 9:45pm

ASCO Annual Meeting

Fam-trastuzumab deruxtecan-nxki demonstrated favorable clinical activity with a high objective response rate and durable responses in patients with HER2-mutated non–small cell lung cancer.

May 29th 2020, 9:26pm

ASCO Annual Meeting

Single agent belantamab mafodotin sustained clinically meaningful deep responses and was well tolerated in patients with heavily pretreated relapsed or refractory multiple myeloma.